| Previous Close | 0.0005 |
| Open | 0.0005 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's Range | 0.0003 - 0.0005 |
| 52 Week Range | 0.0000 - 0.4998 |
| Volume | 221,170,654 |
| Avg. Volume | 68,435,663 |
| Market Cap | 303,935 |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -30.3230 |
| Earnings Date | Sep. 07, 2020 - Sep. 10, 2020 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
San Francisco, California, July 01, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Simlatus Corporation (OTC PINK: SIML) (“Simlatus” or the “Company”), announces today that the company has contracted to build its cannabis extraction systems for one of the west coast premier cannabis technology firms. About Simlatus: The company operates multiple revenue streams in the CBD Industry, Major Broadcast Industry and Internet Provider Industry.
San Francisco, CA, June 25, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Simlatus Corporation (OTC PINK: SIML) (“Simlatus” or the “Company”), announces today that its Chairman Richard Hylen is updating shareholders regarding the company's subsidiary, Proscere Bioscience, and the overall financial future of the company including obtaining initial orders totaling $20Mil for its CBD coldwater extraction system. This allows their global operation to produce more efficiently, with less waste and save money.
San Francisco, California, May 20, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Simlatus Corporation (OTC PINK: SIML) (“Simlatus” or the “Company”), announces today that the company has completed its testing and will move forward with Proscere Bioscience’s CBD coldwater extraction systems and initial $20M in orders. Proscere Bioscience will spearhead the revenue for our company.
SAN FRANCISCO, CA, Nov. 12, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – Simlatus Corporation (OTC PINK: SIML) (“Simlatus” or the “Company”), announces today that Proscere Bioscience has secured the rights to manufacture a CBD - Hybrid Extraction System with integrated cold-water and alcohol extraction technologies. Proscere Bioscience will manufacture the world’s first Hybrid Cold-Water/Alcohol Extraction System for CBD. Richard Hylen, CEO, stated, “Having secured the technological rights to build and bring to market the world’s first Hybrid Extraction System for CBD is certainly a game changer for the Company.
San Francisco, California, Oct. 22, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Simlatus Corporation (OTC PINK: SIML) (“Simlatus” or the “Company”), Richard Hylen, Chairman and CEO, has made the following announcement. “In the past year Simlatus has acquired Satel Group and Proscere Bioscience. With this said, I was appointed as the Chairman and CEO of Simlatus on October 31, 2018.
San Francisco, California, Oct. 18, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Simlatus Corporation (OTC PINK: SIML) (“Simlatus” or the “Company”) announces today that Proscere Bioscience will have the rights to manufacture a hybrid CBD Extraction System which combines cold-water extraction with alcohol extraction. Richard Hylen, CEO, stated, “We now have the technology rights to build a CBD extraction system that can process bio-mass through a cold-water extraction processing system first, and through an alcohol extraction system second.
San Francisco, California, Oct. 17, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Simlatus Corporation (OTC PINK: SIML) (“Simlatus” or the “Company”) announces today that certifications and manufacturing processes are initiated to commence the manufacturing and delivery pursuant the purchase orders for the CBD Extraction Systems. Safe Harbor for Forward-Looking Statements: This news release contains forward-looking statements which are not statements of historical fact.
San Francisco, California, Sept. 17, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Simlatus Corporation (OTC PINK: SIML) (“Simlatus” or the “Company”) announces today that between March and August of this year it has prepaid 5 notes for a total principal, interest and penalties of over $2M. Pursuant the 8K filing of September 16, 2019, the company is finalizing the delivery of 14 CBD Extraction Systems in value of $24M. Richard Hylen, CEO, stated, “Whenever possible, we have been prepaying convertible notes and retiring any reserves and shares back to treasury.
Grass Valley, CA, Sept. 11, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Simlatus Corporation (OTC PINK: SIML) ("Simlatus" or the "Company") announces today negotiations with a major pharmaceutical company in Europe regarding a potential $200M initial order. The company initially discussed its Hybrid Cold/Water – Alcohol based CBD Extraction system in Europe last December-2018 with a major pharmaceutical company. Negotiations are gaining ground while Proscere Bioscience is positioning itself to supply the pharmaceutical industry with CBD extraction systems to produce pharmaceutical-grade THC and CBD as a replacement for opiate based Schedule-II prescription drugs.
Richard Hylen, CEO and Chairman, stated, “Since my appointment starting in late 2018 , our company has demonstrated growth in revenue and sales for all 3 of our subsidiaries. Mr. Hylen further stated, “Proscere Bioscience continues to demonstrate strong growth in the growing CBD industry, with our focus on fulfilling $20M+ in purchase orders for our CBD Extraction systems.
San Francisco, California, Aug. 07, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Simlatus Corporation (OTC PINK: SIML) (“Simlatus” or the “Company”) today announces that the Company entered into a Release Agreement in July 2019 and agreed to pre-pay the entire balance of a convertible note dated January 31, 2019 with the original principal amount of $33,000 between Emunah Funding, LLC and SIML. About SIML: While acquisitions of companies in the hemp sector accelerate worldwide as industrial and consumer hemp/CBD markets develop, our Proscere Bioscience is the company’s division focused on the CBD industry with sales over $20M during the first half of 2019 for its Cold-Water Extraction System. Satel Group is one of only a handful of companies holding AT&T contracts to service multi-dwelling units throughout large metropolitan areas in the USA with DirecTV services.
San Francisco, California, July 24, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Simlatus Corporation (OTC PINK: SIML) (“Simlatus” or the “Company”) is a holding company focused on opportunities in the cannabis space. The Company owns and operates a number of subsidiaries with multiple revenue streams. While acquisitions of companies in the hemp sector accelerate worldwide as industrial and consumer hemp/CBD markets develop, our Proscere Bioscience is the company’s division focused on the CBD industry.
San Francisco, California, July 16, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Simlatus Corporation (OTC PINK: SIML) (“Simlatus” or the “Company”) is a holding company focused on opportunities in the cannabis space. The Company owns and operates a number of subsidiaries with multiple revenue streams. While acquisitions of companies in the hemp sector accelerate worldwide as industrial and consumer hemp/CBD markets develop, our Proscere Bioscience is the company’s division focused on the CBD industry.